GLP-1 medications for weight management are FDA-approved for adults who meet one of the following criteria: BMI 30 (obesity), or BMI 27 (overweight) with at least one weight-related condition: Type 2 diabetes, hypertension, high cholesterol, sleep apnea, cardiovascular disease, or MASLD/NAFLD A complete medical evaluation is required before starting any GLP-1 therapy at MWLI
Platforms like MeAgain bring together shot logs, protein and water intake tracking, injection-site records, and side-effect timelines
Other drugs in the Ozempic MDL The other drugs involved in the MDL lawsuits currently include Rybelsus , Wegovy , Mounjaro and Trulicity
Predictive value of neutrophil to lymphocyte ratio in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a metaanalysis
Care Med., 149:86-90 (1994)
GLP-1 adaptation: Appetite suppression is strongest early, then plateaus (Wharton et al., 2023)